New drug combo for relapsed large B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of three drugs (golcadomide, poseltinib, and rituximab) for people with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. It may be an option if you cannot have a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- You must have a specific type of aggressive large B-cell lymphoma (like DLBCL) that has come back or not responded to at least one prior chemotherapy that included an anthracycline drug.
- You must have at least one area of lymphoma that can be seen on a PET or CT scan.
- You must be willing to use effective contraception if you could become pregnant or get someone pregnant.
- You cannot have had a prior stem cell transplant within certain timeframes, active central nervous system lymphoma, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of four drugs (sonrotoclax, glofitamab, gemcitabine, and oxaliplatin) for people with large B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This trial tests a new drug combination for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests a new drug, Golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or hasn't responded to prior treatment. The goal is to see if this combination works better than other treatments your doctor might choose.
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
Hear when a new Large B-Cell Lymphoma (LBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.